Sankyo
Executive Summary
Sankyo USA will become a division of Sankyo Pharma in New York City, effective at the end of the year, with Sankyo USA President Kanichi Nakamura, PhD, as head of Sankyo Pharma. Former Searle VP-Medical Research John Alexander, MD, has been appointed exec VP responsible for U.S. product development
You may also be interested in...
Sankyo Parke Davis Will Double Sales Force To Market GelTex Cholestagel
Sankyo Parke Davis intends to double its sales force to support the marketing and sales of GelTex' cholesterol reduction agent Cholestagel (colesevelam).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011